Additionally, an increased interaction between MAFG and NRF2 was previously observed upon tumor exposure to the kinase inhibitor of sorafenib, whereas NRF2 inhibition promoted the response to sorafenib in HCC (Sun et al., 2016). Here, MAFG is linked to hepatocellular carcinoma.